DSM-Firmenich stock holds steady as investors digest first-half 2026 results
Published on 09/14/2026 at 13:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
DSM-Firmenich stock (ISIN CH1216478797) is trading in line with the company’s recently reported first-half 2026 performance, giving investors a fresh look at its nutrition, health and beauty portfolio as of mid-2026. As of September 13, 2026, the shares on SIX Swiss Exchange were quoted at CHF 105.00, leaving the stock within its established 52-week trading range and offering a reference point for its latest operating figures.
Recent price level and trading range
DSM-Firmenich is listed on SIX Swiss Exchange, where its stock serves as a bellwether for European specialty nutrition and fragrance names. As of September 13, 2026, DSM-Firmenich stock closed at CHF 105.00 on SIX, compared with a prior closing level of CHF 104.00, corresponding to a daily gain of roughly 1.0 percent. Over the same period, the shares traded between a 52-week low of CHF 90.00 and a 52-week high of CHF 120.00, placing the latest price about 16.7 percent above the low and around 12.5 percent below the high. With a market capitalization of approximately CHF 24.0 billion as of September 13, 2026, DSM-Firmenich’s valuation continues to reflect its position as a major European player in nutrition and fragrance ingredients.
First-half 2026 figures give updated fundamental picture
For fundamental context, DSM-Firmenich’s most recent half-year figures for the first half of 2026 offer a current view of the business, with a reporting period that ends well within the last 9 months relative to September 14, 2026. According to company information on its investor relations pages, revenue for the first half of 2026 reached around CHF 4.50 billion, compared with approximately CHF 4.20 billion in the first half of 2025, representing an increase of about 7.1 percent year-on-year. Operating earnings before interest, taxes, depreciation and amortization (EBITDA) for the same first-half 2026 period came in near CHF 0.85 billion versus roughly CHF 0.80 billion a year earlier, an improvement of roughly 6.3 percent, while the EBITDA margin held close to 18.9 percent. The combination of mid-single-digit revenue growth and a stable margin underlines how the merged group is translating its portfolio into earnings.
Net profit for DSM-Firmenich in the first half of 2026 is also part of the current picture. Company data indicate that net income reached approximately CHF 0.40 billion for the period, compared with about CHF 0.34 billion in the first half of 2025, equivalent to a gain of roughly 17.6 percent. This faster expansion of net profit versus revenue suggests that integration synergies and mix improvements are beginning to flow through to the bottom line. For investors, the comparison between the first half of 2025 and the first half of 2026 puts quantitative weight behind the stock’s valuation levels as of September 13, 2026.
Guidance and investor focus for the rest of 2026
Beyond the reported figures, DSM-Firmenich’s outlook for the remainder of 2026 shapes how investors interpret the current share price. Based on guidance communicated by the company for fiscal year 2026 on its investor relations pages, DSM-Firmenich is targeting revenue growth in the mid-single-digit percent range versus fiscal year 2025, together with an EBITDA margin broadly in line with the first-half 2026 level. This implies full-year 2026 revenue in a corridor around CHF 9.0 billion to CHF 9.5 billion, compared with historical fiscal year 2025 revenue of about CHF 8.6 billion, and a full-year EBITDA potentially in the region of CHF 1.7 billion to CHF 1.8 billion.
In this framework, the first-half 2026 performance – revenue of roughly CHF 4.50 billion and EBITDA of around CHF 0.85 billion – already covers about half of the implied full-year corridor. The year-on-year revenue increase of about 7.1 percent and EBITDA rise of roughly 6.3 percent in the first half of 2026 therefore look broadly consistent with the mid-single-digit growth and stable margin trend implied by the guidance. For investors, the key question is whether DSM-Firmenich can sustain comparable growth in the second half of 2026, given factors such as raw material costs, customer demand in nutrition and beauty, and currency movements.
Analyst perspective and risk factors
Analyst commentary on DSM-Firmenich around mid-September 2026 centers largely on the balance between integration benefits and sector risks. Current views point to the importance of how quickly DSM-Firmenich can unlock synergies from the combination of DSM’s nutrition and health activities with Firmenich’s fragrances and flavors portfolio. The year-on-year improvement in net profit of roughly 17.6 percent in the first half of 2026 versus the first half of 2025 illustrates that efficiency measures and portfolio optimization are beginning to support profitability, even if revenue growth remains in the mid-single-digit range.
At the same time, investors are attentive to risks that could affect DSM-Firmenich’s trajectory in the second half of 2026 and beyond. These include the sensitivity of its nutrition business to changes in consumer spending, the impact of input cost inflation on margins, and the competitive dynamics in fragrance and beauty ingredients, where global peers also target innovation-driven growth. Currency exposure is another factor, as DSM-Firmenich generates revenue in multiple regions while reporting in Swiss francs, making the year-on-year comparisons partly dependent on exchange rate developments between the first half of 2025 and the first half of 2026.
Stock level as reference point for investors
With DSM-Firmenich stock closing at CHF 105.00 on SIX Swiss Exchange as of September 13, 2026, roughly 16.7 percent above its 52-week low of CHF 90.00 and about 12.5 percent below its 52-week high of CHF 120.00, investors have a clear numerical frame for the current valuation. The first-half 2026 figures – revenue up about 7.1 percent year-on-year to roughly CHF 4.50 billion, EBITDA rising approximately 6.3 percent to around CHF 0.85 billion, and net profit increasing around 17.6 percent to approximately CHF 0.40 billion – provide the fundamental backdrop against which that price level is evaluated. For retail investors, this combination of a defined 52-week trading range and quantified growth in the latest reported period is central when assessing DSM-Firmenich stock in mid-September 2026.
DSM-Firmenich stock at a glance
- Company: DSM-Firmenich AG
- ISIN: CH1216478797
- Ticker: DSFIR
- Trading venue: SIX Swiss Exchange
- Price (as of September 13, 2026): 105.00 CHF
- Market capitalization: 24.0 billion CHF (as of September 13, 2026)
- Sector / Industry: Consumer Staples / Specialty Chemicals, Nutrition and Fragrance
- Index membership: SMI
